

WHAT IS CLAIMED IS:

1. An isolated antibody which binds to Domain 1 of ErbB2.
2. The antibody of claim 1 which binds to epitope 7C2/7F3 on ErbB2.
3. The antibody of claim 1 which induces death of a cell which overexpresses ErbB2.
4. The antibody of claim 3 which induces cell death via apoptosis.
5. The antibody of claim 1 which is a monoclonal antibody.
6. The antibody of claim 1 which has nonhuman complementarity determining region (CDR) residues and human framework region (FR) residues.
7. The antibody of claim 1 which is labelled.
8. The antibody of claim 1 which is immobilized on a solid phase.
9. An isolated antibody which binds to ErbB2 and induces apoptosis of a cell which overexpresses ErbB2.
10. The antibody of claim 9 wherein the cell is a BT474 cell.
11. The antibody of claim 9 wherein the cell is a SKBR3 cell.
12. The antibody of claim 9 wherein the cell is a Calu 3 cell.
13. The antibody of claim 1 which has complementarity determining regions (CDRs) of antibody 7C2 .
14. The antibody of claim 1 which has complementarity determining regions (CDRs) of antibody 7F3.

15. A composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
16. The composition of claim 15 further comprising a second anti-ErbB2 antibody which does not bind to Domain 1 of ErbB2.
17. The composition of claim 15 further comprising a second antibody which binds ErbB2 and inhibits growth of SKBR3 cells in cell culture by 50-100%.
18. The composition of claim 17 wherein the second antibody binds to epitope 4D5 on ErbB2.
19. The composition of claim 18 wherein the second antibody has complementarity determining regions (CDRs) of antibody 4D5.
20. The composition of claim 15 that is sterile.
21. Nucleic acid encoding the antibody of claim 1.
22. A vector comprising the nucleic acid of claim 21.
23. A host cell comprising the nucleic acid of claim 21.
24. The host cell of claim 23 which is a hybridoma cell line producing antibody 7C2 or 7F3.
25. A method for making an anti-ErbB2 antibody comprising culturing the host cell of claim 23 so that the anti-ErbB2 antibody is expressed and recovering the anti-ErbB2 antibody from the host cell culture.
26. A method for determining the presence of ErbB2 comprising exposing a cell suspected of containing ErbB2 to the antibody of claim 1 and determining binding of said antibody to the cell.

27. A kit comprising the antibody of claim 1 and instructions for using the antibody to detect ErbB2.

*Sub-Office*  
~~28. A method for inducing cell death comprising exposing a cell which overexpresses ErbB2 to an effective amount of the antibody of claim 1.~~

29. The method of claim 28 wherein the cell is a cancer cell.

30. The method of claim 28 wherein the cell is in a mammal.

31. The method of claim 30 wherein the mammal is a human.

*Office*  
~~32. The method of claim 28 further comprising exposing the cell to a second anti-ErbB2 antibody which does not bind to Domain 1 of ErbB2.~~

33. The method of claim 28 further comprising exposing the cell to a second antibody which binds ErbB2 and inhibits growth of SKBR3 cells in cell culture by 50-100%.

*Office*  
~~34. The method of claim 33 wherein the cell is exposed to the antibody which binds to Domain 1 of ErbB2 before the cell is exposed to the second antibody.~~

35. The method of claim 33 wherein the second antibody binds to epitope 4D5 on ErbB2.

36. The method of claim 35 wherein the second antibody has complementarity determining regions (CDRs) of antibody 4D5.

37. The method of claim 28 further comprising exposing the cell to a growth inhibitory agent.

38. The method of claim 28 further comprising exposing the cell to a chemotherapeutic agent.

39. The method of claim 28 further comprising exposing the cell to radiation.

~~Subt  $a^3$~~ 

a container;  
a label on the container; and  
a composition comprising an active agent contained within the container; wherein the composition is effective for inducing cell death, the label on the container indicates that the composition can be used for treating conditions characterized by overexpression of ErbB2 and the active agent in the composition is the antibody of claim 1.

add  
a<sup>4</sup>

odd  
b'

and 6